Wurzburg biotech flourishing:
This article was originally published in Clinica
Executive Summary
The German city of Wurzburg is making a name for itself as a centre for biomedicine. Two companies from the area, OncoMab and Osteogenetics, took first and second prize in the recently held Businessplan-Competition (Businessplan-Wettbewerb) for North Bavaria, which aims to initiate the foundation of innovative companies and lend support during their preliminary growth phase. OncoMab is a spin-off from the pathology institute of the University of Wurzburg and is involved in the development of human monoclonal antibodies for use in cancer therapy. The advantage of human anti-bodies, says the company, is that, while they are the "most effective" method of combating chronic disease, they are extremely well tolerated by the patient. Osteogenetics, founded by two oral surgeons from Wurzburg, develops biomaterials used in the healing of bone defects. The company intends to focus on the employment of bone growth factors in the regeneration of cartilage. The Businessplan-Wettbewerb was originally established in various regions of Germany by McKinsey & Co to support innovative, mainly scientific start-up companies. The competitions now have a wider group of sponsors.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.